Cannabix Enters Sales Distribution Agreement with Alco Prevention Canada for BreathLogix Autonomous Alcohol Breathalyzer
Rhea-AI Summary
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) has signed a non-exclusive distribution agreement with Alco Prevention Canada for North America to distribute its BreathLogix autonomous alcohol breathalyzer devices. Alco Prevention, based in Montreal, has 4,000 points of sale and 45 agents worldwide.
The BreathLogix device features patent-pending pre-calibrated cartridge technology, eliminating the need for costly calibration equipment and technician visits. The system autonomously performs alcohol screening, captures user photos for identity confirmation, and delivers real-time BAC results with automated reporting via text, email, and web portal.
The device is currently being used by the Friedel Clinic in Montana under the 24/7 Sobriety Program, demonstrating cost and time savings by eliminating the need for dedicated screening administrators. The company is in discussions with additional distributors in North America and other regions.
Positive
- Non-exclusive distribution agreement secured with established distributor having 4,000 points of sale
- Patent-pending technology reduces maintenance costs and eliminates need for technician visits
- Real-world implementation proving cost and time savings for clients
- Additional distribution discussions ongoing for market expansion
Negative
- Non-exclusive nature of distribution agreement may limit competitive advantage
- Success dependent on market adoption and competition in breath testing segment
News Market Reaction
On the day this news was published, BLOZF gained 9.59%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Cannabix has developed an autonomous alcohol breathalyzer screening device for employers and a range of industries and safety settings
VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath devices is pleased to report that it has entered into a non-exclusive distribution agreement (“Agreement”) with Alco Prevention Canada (“Alco Prevention”) for North America for its BreathLogix autonomous (unmanned) alcohol breathalyzer devices (Figures 1 and 2). The Company is in discussions with additional distributors in North America and elsewhere.
Alco Prevention, based in Montreal has 4,000 points of sale and is represented by 45 agents worldwide. Alco Prevention offers consumers electronic breathalyzers, breathalyzer rentals for corporate events, training programs, intervention policies and procedures as well as drug screening tests.
Stephane Maurais, General Manager of Alco Prevention stated, “The Breath Logix alcohol device is one the most compact and feature rich devices I have seen in a long time. The device is well suited for employer pre-access, work sites, construction, bars, hotels, restaurants and other safety sensitive environments. The device allows employees and patrons to self-test for breath alcohol, avoiding the cost of having to pay an administrator –this saves time and money for customers and makes workplace safety programs easier to deploy. We are very pleased to represent this Canadian built product.”
Rav Mlait, CEO of Cannabix Technologies stated, “Cannabix is delivering truly innovative new technologies in breath testing to the marketplace. Breath testing for marijuana and alcohol is a growing segment, ripe for innovation and disruptive technologies –this has been our focus, and we look forward to reaching new milestones in 2025.”
Figure 1. BreathLogix Alcohol Screening Devices
Figure 2. BreathLogix Alcohol device available with contactless and straw modes for rapid pre-access alcohol screening
BreathLogix Alcohol Screening Devices
The Company’s BreathLogix unmanned alcohol screening devices hosts several features including patent pending pre-calibrated cartridge technology which will allow administrators to easily maintain their devices, and eliminate the need for costly calibration equipment and time-consuming site visits from technicians for maintenance. The devices can be used for pre-access alcohol testing, random testing, start-of-shift testing, pre-employment testing, return-to-work testing and post-incident testing.
BreathLogix autonomously checks the sobriety of a user and can take a picture to confirm and record identity while a breath sample is being delivered. Upon detection of positive breath alcohol result, the device will deliver a precise Blood Alcohol Content (BAC) level on the screen, and send a real-time test report via text message, e-mail and to a dedicated web portal. Furthermore, the system logs user test reports for incident reporting and historical investigations.
For example, under the 24/7 Sobriety Program (deployed in several US states to reduce the re-arrests of individuals previously convicted of driving while under the influence of alcohol through daily breath testing) the BreathLogix device is currently helping the Friedel Clinic (Montana) save money, time and resources by autonomously collecting breath samples from clients on a daily basis, eliminating the need for dedicated in-house alcohol screening administrators using conventional handheld devices.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol breath technologies for workplaces, law enforcement and other settings. Breath testing for delta-9 THC (the primary psychoactive ingredient in cannabis) focuses on recent marijuana use. Cannabix is the developer of the BreathLogix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
For further information, contact the Company at info@cannabixtechnologies.com
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements relating to: certification of devices, acceptance of devices by international regulators, the achievement of any or all of the goals and aims of the distribution and sales agreement with any third-party companies ; the completion of pre-validation or validation testing described in this news release; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company's products; the negotiation and potential entry into additional agreements with distributors; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that the Company’s development of cannabis and alcohol breathalyzer technologies will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/ed76ae95-1497-442d-9080-559a53b5426d
https://www.globenewswire.com/NewsRoom/AttachmentNg/f1016da3-33cd-4ca4-ad4c-2b2538da2a3b
FAQ
What are the key features of Cannabix's BreathLogix alcohol screening device (BLOZF)?
How does the BreathLogix distribution agreement with Alco Prevention impact BLOZF's market reach?
What types of testing can the BreathLogix device perform for employers?
How is the BreathLogix device being implemented in real-world applications?
